Home » Stocks » PYPD

PolyPid Ltd. (PYPD)

Stock Price: $10.40 USD -0.40 (-3.70%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 192.34M
Revenue (ttm) n/a
Net Income (ttm) 6.91M
Shares Out 562,451
EPS (ttm) -23.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $10.40
Previous Close $10.80
Change ($) -0.40
Change (%) -3.70%
Day's Open 10.80
Day's Range 10.40 - 10.80
Day's Volume 41,295
52-Week Range 8.89 - 19.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 weeks ago

Single Local Treatment of OncoPLEX Showed Improved Overall Survival and Significantly Less Tumor Recurrence, and Reduced Systemic Toxicity Compared to Multiple Injections with Standard Systemi...

GlobeNewsWire - 4 weeks ago

Enrollment in SHIELD I, the First Phase 3 Clinical Trial Continues to Progress, with Top-line Data Anticipated in Second Half of 2021

GlobeNewsWire - 1 month ago

PETAH TIKVA, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered, and...

GlobeNewsWire - 1 month ago

PETAH TIKVA, Israel, Nov. 24, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and ...

Seeking Alpha - 2 months ago

PolyPid Ltd. (PYPD) CEO Amir Weisberg on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

•  Over 50% of p lanned 60 centers for ongoing Phase 3 SHIELD I t rial of D-PLEX 100 in a bdominal s urgery have r eceived IRB approval 

GlobeNewsWire - 2 months ago

PETAH TIKVA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and ...

GlobeNewsWire - 2 months ago

PETAH TIKVA, Israel, Oct. 28, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and ...

Seeking Alpha - 4 months ago

PolyPid Ltd. (PYPD) CEO Amir Weisberg on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 4 months ago

Initiated Phase 3 SHIELD I Trial for D-PLEX100 in Abdominal Surgery and Received Fast Track Designation for D-PLEX100 from FDA

GlobeNewsWire - 5 months ago

PETAH TIKVA, Israel, Aug. 05, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered an...

GlobeNewsWire - 5 months ago

PETAH TIKVA, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered an...

GlobeNewsWire - 5 months ago

PETAH TIKVA, Israel, July 27, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered an...

Seeking Alpha - 6 months ago

Polypid starts phase 3 trial in prevention of post-abdominal surgery incisional infection.

Market Watch - 6 months ago

PolyPid disclosed Monday that it set terms for its initial public offering, in which the Israel-based biopharmaceutical company expects to raise up to $53.1 million. The company is offering 3...

About PYPD

PolyPid develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix platform. Its products include D-PLEX, an antibiotic drug reservoir that is implanted during surgery to prevent and treat surgical site infections; D-PLEX100 for the prevention of post-abdominal surgery incisional infection; BONYPID-1000, an antibiotic eluting ß tri-calcium phosphate granule for bone related infections applications; and BONYPID?500, an antibiotic eluting bone graft substitute that fills and reconstructs periodontal and oral/... [Read more...]

Industry
Biotechnology
IPO Date
Jun 26, 2020
CEO
Amir Weisberg
Employees
57
Stock Exchange
NASDAQ
Ticker Symbol
PYPD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for PolyPid stock is "Buy." The 12-month stock price forecast is 25.80, which is an increase of 148.08% from the latest price.

Price Target
$25.80
(148.08% upside)
Analyst Consensus: Buy